CA2366793A1 - Propofol formulation with enhanced microbial characteristics - Google Patents

Propofol formulation with enhanced microbial characteristics Download PDF

Info

Publication number
CA2366793A1
CA2366793A1 CA002366793A CA2366793A CA2366793A1 CA 2366793 A1 CA2366793 A1 CA 2366793A1 CA 002366793 A CA002366793 A CA 002366793A CA 2366793 A CA2366793 A CA 2366793A CA 2366793 A1 CA2366793 A1 CA 2366793A1
Authority
CA
Canada
Prior art keywords
formulation
microbial
propofol
soybean oil
nutrients
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002366793A
Other languages
French (fr)
Other versions
CA2366793C (en
Inventor
Satish K. Pejaver
Rajeshwar Motheram
Barrett E. Rabinow
Josben C. Dela Rosa
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Baxter International Inc
Original Assignee
Baxter International Inc.
Satish K. Pejaver
Rajeshwar Motheram
Barrett E. Rabinow
Josben C. Dela Rosa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baxter International Inc., Satish K. Pejaver, Rajeshwar Motheram, Barrett E. Rabinow, Josben C. Dela Rosa filed Critical Baxter International Inc.
Publication of CA2366793A1 publication Critical patent/CA2366793A1/en
Application granted granted Critical
Publication of CA2366793C publication Critical patent/CA2366793C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

Formulations of intravenous anesthetic propofol emulsions are provided which contain sufficiently low concentrations of soybean oil to produce a stable emulsion and simultaneously provide reduced nutrients, which inhibit microbial growth thereby providing protection against accidental microbial contamination during long-term IV infusions. In addition to the inhibition of microbial growth due to a reduction of nutrients, the formulation exhibits unanticipated additional microbial inhibition due to an increased availability of propofol.
The low concentration of soybean oil also provides a formulation that reduces the chances of fat overload when administered over an extended period of time to chronically ill patients.
CA002366793A 1999-04-05 2000-03-29 Propofol formulation with enhanced microbial characteristics Expired - Fee Related CA2366793C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US09/286,159 US6100302A (en) 1999-04-05 1999-04-05 Propofol formulation with enhanced microbial characteristics
US09/286,159 1999-04-05
PCT/US2000/008378 WO2000059471A1 (en) 1999-04-05 2000-03-29 Propofol formulation with enhanced microbial characteristics

Publications (2)

Publication Number Publication Date
CA2366793A1 true CA2366793A1 (en) 2000-10-12
CA2366793C CA2366793C (en) 2009-06-02

Family

ID=23097354

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002366793A Expired - Fee Related CA2366793C (en) 1999-04-05 2000-03-29 Propofol formulation with enhanced microbial characteristics

Country Status (9)

Country Link
US (1) US6100302A (en)
EP (1) EP1165045A1 (en)
JP (1) JP2002541086A (en)
KR (2) KR100741604B1 (en)
AU (1) AU774259B2 (en)
BR (1) BR0009541A (en)
CA (1) CA2366793C (en)
MX (1) MXPA01010064A (en)
WO (1) WO2000059471A1 (en)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6749868B1 (en) 1993-02-22 2004-06-15 American Bioscience, Inc. Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof
AU6689601A (en) * 2000-06-16 2002-01-02 Rtp Pharma Inc Improved injectable dispersions of propofol
US6399087B1 (en) * 2000-12-20 2002-06-04 Amphastar Pharmaceuticals, Inc. Propofol formulation with enhanced microbial inhibition
US20030054042A1 (en) * 2001-09-14 2003-03-20 Elaine Liversidge Stabilization of chemical compounds using nanoparticulate formulations
WO2003026632A2 (en) 2001-09-26 2003-04-03 Theravance, Inc. Substituted phenol compounds useful for anesthesia and sedation
CA2461349C (en) 2001-09-26 2011-11-29 Baxter International Inc. Preparation of submicron sized nanoparticles via dispersion and solvent or liquid phase removal
JP4842514B2 (en) * 2002-03-20 2011-12-21 エラン ファーマ インターナショナル，リミティド Nanoparticle composition of angiogenesis inhibitor
KR100459025B1 (en) * 2002-05-02 2004-12-03 (주) 에프디엘 Novel composition comprising propofol for the use of injection
AU2003222491A1 (en) * 2002-05-02 2003-12-31 Fdl, Inc. Novel parenteral composition comprising propofol
WO2004010941A2 (en) * 2002-07-29 2004-02-05 Transform Pharmaceuticals, Inc. Aqueous 2,6-diisopropylphenol pharmaceutical compositions
US7550155B2 (en) * 2002-07-29 2009-06-23 Transform Pharmaceuticals Inc. Aqueous pharmaceutical compositions of 2,6-diisopropylphenol (propofol) and their uses
JP2006504771A (en) * 2002-10-29 2006-02-09 トランスフォーム・ファーマシューティカルズ・インコーポレイテッド Propofol with cysteine
EP2359859A1 (en) 2002-12-09 2011-08-24 Abraxis BioScience, LLC Compositions comprising albumin nanoparticles and methods of delivery of pharmacological agents
US20040225022A1 (en) * 2003-05-09 2004-11-11 Desai Neil P. Propofol formulation containing reduced oil and surfactants
US8476010B2 (en) 2003-07-10 2013-07-02 App Pharmaceuticals Llc Propofol formulations with non-reactive container closures
US8546453B2 (en) 2003-08-14 2013-10-01 Rensheng Zhang Propofol compositions and methods for reducing pain associated with propofol injection
EP1799266A2 (en) * 2004-09-13 2007-06-27 Bharat Serums & Vaccines Ltd. Stable emulsion compositions for intravenous administration having antimicrobial preservative efficacy
ES2318802T3 (en) * 2005-08-05 2009-05-01 BHARAT SERUMS & VACCINES LTD. INTRAVENOUS PROPOFOL EMULSION COMPOSITIONS THAT HAVE CONSERVATIVE EFFECTIVENESS.
US20090203794A1 (en) * 2005-08-12 2009-08-13 Gautam Vinod Daftary Aqueous Anaesthetic Composition Comprising Propofol
US7771751B2 (en) 2005-08-31 2010-08-10 Abraxis Bioscience, Llc Compositions comprising poorly water soluble pharmaceutical agents and antimicrobial agents
EP3527202A1 (en) * 2005-08-31 2019-08-21 Abraxis BioScience, LLC Compositions and methods for preparation of poorly water soluble drugs with increased stability
US8722736B2 (en) 2007-05-22 2014-05-13 Baxter International Inc. Multi-dose concentrate esmolol with benzyl alcohol
US8426467B2 (en) 2007-05-22 2013-04-23 Baxter International Inc. Colored esmolol concentrate
JP2013001700A (en) * 2011-06-21 2013-01-07 Fujifilm Corp Propofol-containing oil-in-water type emulsion composition
JP5759804B2 (en) * 2011-06-27 2015-08-05 富士フイルム株式会社 Container preparation
MX2014013826A (en) 2012-05-16 2018-04-24 Singh Mewa Pharmaceutical compositions for the delivery of substantially water-insoluble drugs.
CN104490780B (en) * 2015-01-16 2017-04-19 河北一品制药有限公司 Preparation method of propofol fat emulsion injection
US11622937B2 (en) 2015-08-20 2023-04-11 Mewa Singh Polyphenolic polymer to make water-insoluble molecules become water-soluble
CN110478366A (en) * 2019-08-23 2019-11-22 宜昌人福药业有限责任公司 Topical compositions and its preparation method and application containing water-insoluble antalgesic

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1472793A (en) * 1974-03-28 1977-05-04 Ici Ltd Pharmaceutical compositions
NZ279952A (en) * 1994-02-04 1998-02-26 Scotia Lipidteknik Ab Oil-in-water emulsion comprising digalactosyldiacylglycerols as carrier
GB9405593D0 (en) * 1994-03-22 1994-05-11 Zeneca Ltd Pharmaceutical compositions
US5637625A (en) * 1996-03-19 1997-06-10 Research Triangle Pharmaceuticals Ltd. Propofol microdroplet formulations
AU759641B2 (en) * 1998-08-19 2003-04-17 Skyepharma Canada Inc. Injectable aqueous dispersions of propofol
US6140374A (en) * 1998-10-23 2000-10-31 Abbott Laboratories Propofol composition

Also Published As

Publication number Publication date
KR20010112400A (en) 2001-12-20
BR0009541A (en) 2002-01-02
MXPA01010064A (en) 2002-06-21
KR100861820B1 (en) 2008-10-07
US6100302A (en) 2000-08-08
JP2002541086A (en) 2002-12-03
AU4046300A (en) 2000-10-23
KR100741604B1 (en) 2007-07-20
KR20070058012A (en) 2007-06-07
EP1165045A1 (en) 2002-01-02
WO2000059471A1 (en) 2000-10-12
AU774259B2 (en) 2004-06-24
CA2366793C (en) 2009-06-02

Similar Documents

Publication Publication Date Title
CA2366793A1 (en) Propofol formulation with enhanced microbial characteristics
WO2001078701A3 (en) Method and compositions for preventing hormone induced adverse effects
CA2397990A1 (en) Propofol formulation with enhanced microbial inhibition
US20050266083A1 (en) Vehicles for delivery of biologically active substances
JP2002528405A (en) Propofol composition
US20070190014A1 (en) Oil - in - polyhydric alcohol type warming base agent
AP1666A (en) Quinolinone derivatives as tyrosine kinase inhibitors.
EA003771B1 (en) Propofol composition comprising pentetate
WO2007048645A3 (en) Protection of oxidizable agents
CA2595489A1 (en) Synergistic preservative systems comprising glycols and enzymes, and their use in topical compositions
US6328984B1 (en) Selective antibacterial composition
PL311637A1 (en) Poured over preparations containing a polymer as well as glycerides and glycols
AU5673399A (en) Compositions and methods for treating intracellular infections
KR930001903A (en) Ubide carrenone oral aqueous solution preparation
MX2007002941A (en) Stable emulsion compositions for intravenous administration having antimicrobial preservative efficacy.
JP5507146B2 (en) Water-in-oil emulsified paste pharmaceutical preparation for lips
KR100903708B1 (en) Cosmetics
DE69809435D1 (en) INHIBITOR AND PRESERVATIVE COMPOSITION
JPS6471439A (en) Freshness retaining agent for fishes and shellfishes
GB0018322D0 (en) Pharmaceutical compositions
EP1103269A4 (en) Preparations for the administration of hepatocyte growth factor
ES2179667T3 (en) NEW INJECTABLE FORMULATIONS CONTAINING RAMOPLANIN.
AU2001275925B2 (en) Propofol formulation with enhanced microbial inhibition
LT2001072A (en) Food additive
PL339851A1 (en) Aqueous preparation having fungicidal, insecticidal and bactericidal properties, method of stabilising aqueous preparations, binding agent and application thereof

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed